CSF3 and leukemia: The main question is the risk-benefit ratio, as mentioned in the very first article reporting the effect of G-CSF in this setting [161], particularly as leukemias had been observed in the rare patients with congenital neutropenia who survived beyond their first decade of life [192-194].